Nothing Special   »   [go: up one dir, main page]

PT2297115E - Derivados de quinazolina - Google Patents

Derivados de quinazolina Download PDF

Info

Publication number
PT2297115E
PT2297115E PT97437834T PT09743783T PT2297115E PT 2297115 E PT2297115 E PT 2297115E PT 97437834 T PT97437834 T PT 97437834T PT 09743783 T PT09743783 T PT 09743783T PT 2297115 E PT2297115 E PT 2297115E
Authority
PT
Portugal
Prior art keywords
dialkoxyquinazoline
derivatives
kdr inhibitors
kdr
inhibitors
Prior art date
Application number
PT97437834T
Other languages
English (en)
Inventor
Yumin Cui
Jifeng Duan
Wei-Guo Su
Weihan Zhang
Xiaoqiang Yan
Yongxin Ren
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of PT2297115E publication Critical patent/PT2297115E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97437834T 2008-05-09 2009-05-08 Derivados de quinazolina PT2297115E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/118,019 US7829574B2 (en) 2008-05-09 2008-05-09 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Publications (1)

Publication Number Publication Date
PT2297115E true PT2297115E (pt) 2015-10-26

Family

ID=41265455

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97437834T PT2297115E (pt) 2008-05-09 2009-05-08 Derivados de quinazolina

Country Status (22)

Country Link
US (3) US7829574B2 (pt)
EP (1) EP2297115B1 (pt)
JP (2) JP5856842B2 (pt)
KR (2) KR20160045925A (pt)
AU (1) AU2009244130B2 (pt)
BR (1) BRPI0908675B1 (pt)
CA (1) CA2723148C (pt)
CY (1) CY1117222T1 (pt)
DK (1) DK2297115T3 (pt)
ES (1) ES2550245T3 (pt)
HR (1) HRP20150954T1 (pt)
HU (1) HUE025723T2 (pt)
MX (2) MX340021B (pt)
MY (1) MY155566A (pt)
NZ (1) NZ588900A (pt)
PH (1) PH12013500363A1 (pt)
PL (1) PL2297115T3 (pt)
PT (1) PT2297115E (pt)
RU (1) RU2506261C2 (pt)
SI (1) SI2297115T1 (pt)
TW (1) TWI458724B (pt)
WO (1) WO2009137797A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
WO2010093419A1 (en) * 2009-02-11 2010-08-19 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
SI2473487T1 (sl) 2009-09-03 2017-02-28 Bristol-Myers Squibb Company Kinazolini kot ionski kanalni inhibitorji kalija
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
WO2019014044A1 (en) 2017-07-12 2019-01-17 The Johns Hopkins University ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
WO2019183916A1 (zh) * 2018-03-30 2019-10-03 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
EP3837286A4 (en) 2018-08-16 2022-08-10 The Johns Hopkins University ANTIBODIES TO HUMAN ZNT8
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN110898065A (zh) * 2019-11-25 2020-03-24 南通大学 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途
BR112023021111A2 (pt) 2021-04-13 2023-12-19 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
HU230000B1 (en) * 1999-02-10 2015-04-28 Astrazeneca Ab Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
DE10009267A1 (de) 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002030924A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
US20040092750A1 (en) 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
WO2003048159A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
AU2004255581A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
AU2004309166B2 (en) * 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
US20080268460A1 (en) * 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
US20070299092A1 (en) 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
WO2007066181A2 (en) 2005-12-05 2007-06-14 Pfizer Products Inc. Methods of preparing a vegf-r inhibitor
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
AU2007249762A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of CDKI pathway inhibitors
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Also Published As

Publication number Publication date
AU2009244130A1 (en) 2009-11-12
AU2009244130B2 (en) 2012-11-01
KR20160045925A (ko) 2016-04-27
PL2297115T3 (pl) 2015-12-31
BRPI0908675A2 (pt) 2015-08-04
MX2014001023A (es) 2014-05-22
WO2009137797A3 (en) 2010-02-25
ES2550245T3 (es) 2015-11-05
WO2009137797A2 (en) 2009-11-12
US7829574B2 (en) 2010-11-09
CY1117222T1 (el) 2017-04-05
EP2297115A4 (en) 2012-03-14
DK2297115T3 (en) 2015-08-10
MX2010012168A (es) 2011-02-18
US8497372B2 (en) 2013-07-30
NZ588900A (en) 2012-12-21
HUE025723T2 (en) 2016-04-28
JP2014177499A (ja) 2014-09-25
KR101686679B1 (ko) 2016-12-14
US20120238572A1 (en) 2012-09-20
BRPI0908675B1 (pt) 2022-01-25
TW201002694A (en) 2010-01-16
US20090281130A1 (en) 2009-11-12
RU2010150345A (ru) 2012-06-20
US8212033B2 (en) 2012-07-03
JP5856842B2 (ja) 2016-02-10
EP2297115A2 (en) 2011-03-23
HRP20150954T1 (hr) 2015-10-09
JP2011519956A (ja) 2011-07-14
EP2297115B1 (en) 2015-07-22
US20110015213A1 (en) 2011-01-20
SI2297115T1 (sl) 2015-10-30
MX340021B (es) 2016-06-22
CA2723148C (en) 2015-01-20
CA2723148A1 (en) 2009-11-12
PH12013500363A1 (en) 2013-09-02
RU2506261C2 (ru) 2014-02-10
MY155566A (en) 2015-10-30
KR20110013381A (ko) 2011-02-09
TWI458724B (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
HK1256310A1 (zh) N-磺酰基吡咯衍生物
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
PT2297115E (pt) Derivados de quinazolina
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
ZA201102449B (en) Morpholinopurine derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL208626A0 (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
ZA201105050B (en) Quinazolinamide derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
GB0821710D0 (en) Derivatives of dihydroindolone
HUP0800376A2 (en) Sulfonyl-quinoline derivatives
GB0821711D0 (en) Dihydroindolone derivatives
GB0816145D0 (en) a-Galactosylceramide derivatives